MYNZ – mainz biomed b.v. (US:NASDAQ)

News

Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting
Mainz Biomed Provides Review of 2025 Highlights [Yahoo! Finance]
Mainz Biomed Provides Review of 2025 Highlights
Mainz Biomed (NASDAQ:MYNZ) was upgraded by analysts at Wall Street Zen
Mainz Biomed (NASDAQ:MYNZ) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com